1
Home
Companies

Altimmune

#7537

Rank

$371.47M

Marketcap

US United States

Country

Altimmune
Leadership team

Dr. Vipin K. Garg Ph.D. (Pres, CEO & Director)

Mr. Richard I. Eisenstadt M.B.A. (Chief Financial Officer)

Dr. M. Scot Roberts Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Clinical Trials, Health Care, Test and Measurement
Headquarters
Gaithersburg, Maryland, United States
Established
1997
Company Registration
SEC CIK number: 0001326190
Revenue
2M - 5M
Traded as
ALT
Social Media
URL
https://altimmune.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
History

Altimmune was founded in October 2015 with a mission to create next generation vaccines and immunotherapeutics. Led by a seasoned management team, Altimmune seeks to bring to market products based on its innovative technologies, aimed at addressing unmet medical needs worldwide.

Mission
Altimmune is dedicated to developing high-value, differentiated products to address unmet medical needs worldwide for a broad range of conditions.
Vision
We strive to be synonymous with the best in immune health and quality, delivering innovative therapeutics that optimize the power of the immune system.
Key Team

Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS (Chief Medical Officer)

Mr. Bertrand Georges Ph.D. (Chief Technology Officer)

Mr. Tony Blandin B.S. (VP of Quality & Compliance Management)

Mr. José Ochoa (Chief Bus. Officer)

Mr. Kent A. Tapper BSEE (Corp. Controller)

Recognition and Awards
Altimmune has been recognized with various awards and fellowships, including the National Institutes of Health's awards and the National Science Foundation's graduate fellowships.
References

https://in.investing.com/equities/pharmathene-inc-company-profile

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/vaxin-inc

https://finance.yahoo.com/q?s=alt

https://altimmune.com

https://sec.report/CIK/0001326190

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Altimmune
Leadership team

Dr. Vipin K. Garg Ph.D. (Pres, CEO & Director)

Mr. Richard I. Eisenstadt M.B.A. (Chief Financial Officer)

Dr. M. Scot Roberts Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Clinical Trials, Health Care, Test and Measurement
Headquarters
Gaithersburg, Maryland, United States
Established
1997
Company Registration
SEC CIK number: 0001326190
Revenue
2M - 5M
Traded as
ALT
Social Media
URL
https://altimmune.com